From Hot Flashes to Healthspan The FxMed Guide to Hormones and Longevity

The speakers emphasize that the foundational pieces—diet, exercise, sleep, community—are non-negotiable pillars. The host shares how resistance training became a habit for her initially to address knee injury, then continued because of its mental health and bone benefits. The guest notes that many women ignore bone health in their 30s and 40s, only focusing on immediate symptoms like belly fat and hot flashes, but bone density and muscle mass compound over decades. Without resistance training and protein, they risk frailty, falls, and fractures later.

The guest explains that while sleep hygiene is critical, sometimes women need exogenous melatonin because their endogenous production has declined. She frequently uses melatonin in her practice, often as a lozenge, and suggests that a microdose taken during the 2-4 a.m. wake-up can help women fall back asleep without causing morning grogginess. She highlights that melatonin's wide-ranging benefits—antioxidant, insulin-sensitizing, blood pressure lowering—mean it should be considered beyond just sleep. The host shares that she uses melatonin lozenges and microchip doses for her own nighttime awakenings.

The guest describes how hormone therapy has evolved from a blanket 'lowest dose for shortest time' to personalized shared decision-making. The speaker details her recent conversation with a woman who was denied hormones due to ocular migraines, yet research supports transdermal estrogen in such cases. She explains that after thorough evaluation, even women with history of breast cancer or fibroids can often use progesterone or vaginal estradiol. The host and guest debate the oral vs. transdermal issue, acknowledging that most brain-health data comes from oral preparations, but that transdermal remains the default for clot safety.

The speaker emphasizes that mitochondria are like 'fragile beans'—they need protection from environmental assaults (endocrine disruptors, heavy metals, inflammation) and support from cofactors. She was validated after a 2024 review confirmed the mitochondrial theory of ovarian aging. While hormone therapy can bypass mitochondrial block, she prefers to support the terrain with lifestyle and nutrients first, as this also prevents metabolic and neurodegenerative consequences.

The speaker describes her personal experience: gray pixelated vision loss in right eye starting at 48, coinciding with her period. After workup with eye doctor and blood tests, both her ND and MD agreed topical estradiol and progesterone were safe. She emphasizes that the fear-based blanket refusal by some physicians is outdated. She advises women to do their due diligence and get worked up, not self-diagnose with ChatGPT.

The speaker notes that melatonin's 2-4 a.m. spike drops core body temperature, lowers blood pressure, and regulates insulin. Perimenopausal women frequently wake at this exact window, often attributed to cortisol or blood sugar, but it may be a failure of the melatonin surge. Melatonin's metabolite cascade acts like 'Russian nesting dolls'—each metabolite can scavenge a reactive oxygen species, making it multiple rounds of quenching. The speaker argues it rivals or exceeds glutathione in antioxidant capacity. Oral melatonin supplementation, especially sustained-release, timed properly, can mitigate the 3 a.m. awakening, but individual sensitivity varies widely; she starts with microdoses (0.3-0.5 mg) and titrates up. The 50-year-old decline in endogenous production aligns with the onset of metabolic and sleep disruptions in women.

The speaker describes seeing men on statins with very low cholesterol and low testosterone, and negotiating with cardiologists to add testosterone rather than reduce statin. This taught her the importance of personalized hormone therapy. She notes that even her own primary care suggested the birth control pill for perimenopause, missing the wider range of options. For oral estrogen, she acknowledges that virtually all brain health data come from oral preparations, and the absolute increased clot risk is 2-3 extra cases per many thousand women. Transdermal avoids first-pass liver effects and is generally preferred for CVD risk, but oral may be unduly maligned. The UK NICE graphics show that conjugated equine estrogen (CEE) actually lowered breast cancer incidence vs. no hormones. The speaker is currently re-evaluating oral estradiol herself and emphasizes that functional medicine should optimize the underlying terrain (fish oil, fibrinogen monitoring) before or alongside any hormone therapy.